4th Quarter - Report

WILLIAMS AND JENSEN, PLLC for PFIZER

Firm
Client
Income
$80,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Drug safety and drug counterfeiting; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009; Health information technology including H.R. 1, the American Recovery and Reinvestment Act; Health care reform including H.R. 3200, America's Affordable Health Choices Act; Affordable Health Choices Act; America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; and H.R. 3590, Patient Protection and Affordable Care Act; Senator Kennedy cancer legislation; Prescription drug advertising; and Federal preemption for prescription drugs.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3590 (111th), H.R. 3200 (111th), S. 525 (111th), S. 1232 (111th), H.R. 1298 (111th), H.R. 1427 (111th), S. 726 (111th), H.R. 3962 (111th), H.R. 1 (111th), S. 1213 (111th), S. 301 (111th), H.R. 1548 (111th)

Labor Issues/Antitrust/Workplace LBR

Wyeth acquisition

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; and Medicare drug price negotiation, payment, and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Prescription Drug Gap Reduction Act of 2009.

LobbyistCovered position, as disclosed
JENNY DIJAMES —
CHRISTOPHER W HATCHER —
SUSAN HIRSCHMANN —
KARINA LYNCH —
MELINDA M MAXFIELD —
GEORGE OLSEN —
JOYCE A ROGERS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 330 (111th), H.R. 1725 (111th), S. 266 (111th), H.R. 684 (111th), S. 547 (111th), H.R. 904 (111th)

Taxation/Internal Revenue Code TAX

Tax issues affecting the pharmaceutical industry including international tax

LobbyistCovered position, as disclosed
CHRISTOPHER W HATCHER —
SUSAN HIRSCHMANN —
KARINA LYNCH —
GEORGE OLSEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.